- Home
- PRPH vs CGTX Comparison
PRPH vs CGTX Comparison
Compare PRPH & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRPH
- CGTX
- Stock Information
- Founded
- PRPH 1989
- CGTX 2007
- Country
- PRPH United States
- CGTX United States
- Employees
- PRPH N/A
- CGTX N/A
- Industry
- PRPH Biotechnology: Pharmaceutical Preparations
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- PRPH Health Care
- CGTX Health Care
- Exchange
- PRPH Nasdaq
- CGTX Nasdaq
- Market Cap
- PRPH 15.5M
- CGTX 16.1M
- IPO Year
- PRPH 1997
- CGTX 2021
- Fundamental
- Price
- PRPH $0.70
- CGTX $0.58
- Analyst Decision
- PRPH Strong Buy
- CGTX Buy
- Analyst Count
- PRPH 1
- CGTX 6
- Target Price
- PRPH $11.00
- CGTX $8.00
- AVG Volume (30 Days)
- PRPH 232.3K
- CGTX 18.0M
- Earning Date
- PRPH 11-13-2024
- CGTX 11-13-2024
- Dividend Yield
- PRPH N/A
- CGTX N/A
- EPS Growth
- PRPH N/A
- CGTX N/A
- EPS
- PRPH N/A
- CGTX N/A
- Revenue
- PRPH $12,753,000.00
- CGTX N/A
- Revenue This Year
- PRPH $36.93
- CGTX N/A
- Revenue Next Year
- PRPH $132.05
- CGTX N/A
- P/E Ratio
- PRPH N/A
- CGTX N/A
- Revenue Growth
- PRPH N/A
- CGTX N/A
- 52 Week Low
- PRPH $0.64
- CGTX $0.34
- 52 Week High
- PRPH $7.48
- CGTX $2.95
- Technical
- Relative Strength Index (RSI)
- PRPH 28.79
- CGTX 65.53
- Support Level
- PRPH $0.66
- CGTX $0.43
- Resistance Level
- PRPH $0.74
- CGTX $0.52
- Average True Range (ATR)
- PRPH 0.06
- CGTX 0.09
- MACD
- PRPH 0.05
- CGTX 0.02
- Stochastic Oscillator
- PRPH 34.44
- CGTX 22.40
About PRPH ProPhase Labs Inc. (DE)
ProPhase Labs Inc is a diversified company that offers a range of services including diagnostic testing, genomics testing and contract manufacturing. Its operating segments include Diagnostic services and Consumer products. The Diagnostic segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third-party payers and government organizations. The Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provide personal genomics products and services.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.